^
Association details:
| Biomarker: | PDE3A overexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | idarubicin hydrochloride (Topoisomerase II inhibitor, DNA cross linking agent) + Agrylin (anagrelide) (Phospholipase A2 inhibitor, PDE3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phosphodiesterase 3A Acts As a Tumor Activator and Its Inhibitor Anagrelide Combined with Idarubicin Represents a Potential Therapeutic Approach for PDE3A High Expressed Acute Myeloid Leukemia through Pyroptosis By Triggering Cleavage of Gasdermin E
Published date:
11/02/2023
Excerpt:
The results demonstrated that the IDA-ANA combination treatment significantly extended the survival time of the mice and reduced the leukemia burden when compared to the individual treatments with either IDA or ANA....In summary, high expression of PDE3A related to poor prognosis in AML and PDE3A inhibitor ANA combined with IDA exerted anti-leukemia effect through pyroptosis on PDE3A high expressed AML.
DOI:
https://doi.org/10.1182/blood-2023-185410
